Our COnsultants

Most recently, Dr. Haskins was Senior Director of Laboratory Sciences in Mattawan, Michigan and Executive Director of Global In Vitro Toxicology in Cleveland, Ohio for Charles River Laboratories (2019-2024). In this role, he managed multidisciplinary teams of professionals providing a broad portfolio of bioanalytical services supporting both pre-clinical and clinical investigations.

Prior to founding The Primordium Group in 2018, Dr. Haskins was Director of Biology and Platform Integration for Protein and Cell Analysis products at Thermo Fisher Scientific in Eugene, Oregon and Pittsburgh, Pennsylvania (2001-2017).  While with Thermo Fisher Scientific, his team developed and released hundreds of innovative products solutions for the life sciences research market, including scientific instrumentation, analytical software, enterprise database solutions, reagents, integrated cellular biosensors, consumables, assay products and custom stem cell media solutions.

Previously, Dr. Haskins was a Senior Research Associate in Drug Safety Evaluation at Pfizer Global Research & Development, Ann Arbor, Michigan Laboratories (1989-2001).  Dr. Haskins laboratory specialized in utilizing a variety of advanced technologies for the development of cytotoxicity screening and profiling applications, as well as mechanistic investigations.  He has extensive experience in early drug discovery programs as well as preclinical development of potential therapeutic candidates.  Prior to joining Parke-Davis, Dr. Haskins was an Industrial Toxicologist for North American Plant Operations of the Ford Motor Company, Dearborn, Michigan (1988-1989). 

Dr. Haskins has significant expertise in program management, developing business strategy and managing strategic planning processes, including financial model development and establishing tools for project prioritization, tracking and visualization.  He is proficient in facilitating decision-making and strategic alignment in a team environment and accomplished at presenting both business opportunities and complex scientific data to mixed audiences of decision makers.  Dr. Haskins has broad technical knowledge in bioanalytical services, cell biology, toxicology, confocal and fluorescence microscopy, flow cytometry, and quantitative image analysis. His technical expertise extends to integration of innovative new technologies into efficient screening workflows for the life sciences and pharmaceutical research markets.

Dr. Haskins received dual B.S. degrees in Chemistry and Biology from Michigan Technological University.  He continued his studies at the University of Michigan where he earned a M.S. degree in Toxicology and a Ph.D. in Environmental Health Sciences, with a focus in Environmental Chemistry and Toxicology. 

Dr. Ghosh is an experienced Senior Program, Project and Platform Manager with over 25 years’ experience developing, applying, and commercializing cutting-edge technologies to different biotechnology areas in academic, start-up, and Fortune 500 organizations. He has a successful record of transforming and integrating disruptive technologies from the research bench into foundational market-leading products for a range of science and technology markets. He is passionate about facilitating and leveraging cross-functional teams and business partners to develop innovative products and solutions to achieve strategic growth. A motivated problem solver and strategic thinker, he has strong analytical, organizational, communication, presentation and interpersonal skills which are easily transferable to other areas. With extensive product development, and project, program, platform, and interdisciplinary scientific management experience, he has developed, mentored, and led several strong multidisciplinary scientific and engineering project teams.

Previously, Dr. Ghosh was a Senior Program Manager in Thermo Fisher Scientific’s Chromatography and Mass Spectrometry division where he led new product development programs and initiatives with globally dispersed cross-functional project teams to develop next-generation products for this market with projected $100M annual revenue. Prior to this, he was the Director of Research and Applications and Principal Scientist in Thermo Fisher Scientific’s Protein and Cellular Analysis Business, which was formed through the merger of several pioneering companies in this area including: Cellomics, Pierce, Molecular Probes and AMG. He has >30 years’ experience of scientific research, and developing and applying quantitative fluorescence microscopy-based imaging technologies to different cell biology areas. He joined Cellomics in 1998 and led R&D teams that developed key High Content Screening cell-based imaging assay tools, such as instruments, reagents, image-analysis software, and assay systems, including the flagship CellInsight CX7 HCS Platform. Before Cellomics, he served on the faculties of Columbia University and Cornell University’s Medical College, where he directed microscopy imaging core facilities, and used quantitative fluorescence microscopy to do research into different cell biology areas. 

Dr. Ghosh received his B.S., M.S. and Ph.D. from Cornell University in Applied Physics specializing in Biophysics, and did postdoctoral research in cell biology at Columbia University.